Replimune Group ((REPL)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Replimune Group is conducting a Phase 1B/2 study titled ‘An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies.’ The study aims to evaluate the objective response rate, safety, and tolerability of RP1 in up to 65 organ transplant recipients with advanced cutaneous malignancies. This research is significant as it targets a vulnerable patient group with limited treatment options.
The intervention being tested is RP1, a genetically modified herpes simplex type 1 virus, administered as an intra-tumoral injection every two weeks. RP1 is designed to treat advanced cutaneous malignancies by targeting and destroying cancer cells.
The study follows an interventional design with a single-group model and no masking, focusing on treatment as the primary purpose. This straightforward approach allows for clear observation of RP1’s effects on the participants.
The study began on April 14, 2020, with a primary completion date yet to be reached. The latest update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and any emerging results.
Market implications of this study update could be significant for Replimune’s stock performance, as successful outcomes may enhance investor confidence and position the company favorably against competitors in the oncolytic virus therapy market.
The study is ongoing, with further details available on the ClinicalTrials portal.